JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 30, 2003; DOI: 10.1124/jpet.103.056184


0022-3565/04/3081-350-357$20.00
JPET 308:350-357, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.056184v1
308/1/350    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pérez-Rivera, A. A.
Right arrow Articles by Galligan, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez-Rivera, A. A.
Right arrow Articles by Galligan, J. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PHENOXYBENZAMINE

CARDIOVASCULAR

Increased Reactivity of Murine Mesenteric Veins to Adrenergic Agonists: Functional Evidence Supporting Increased {alpha}1-Adrenoceptor Reserve in Veins Compared with Arteries

Alex A. Pérez-Rivera, Gregory D. Fink, and James J. Galligan

Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan

These studies examined adrenergic reactivity of mesenteric arteries and veins from deoxycorticosterone acetate-salt (DOCA-salt) hypertensive and sham control mice. We measured constrictions in unpressurized arteries and veins by monitoring vessel diameter using computer-assisted video micros-copy in vitro. Veins were more sensitive than arteries to the constricting effects of norepinephrine (NE) and phenylephrine (PE), but the {alpha}2-agonists clonidine and UK 14,304 [5-bromo-6-(2-imidazolin-2-yl-amino)-quinoxaline] did not constrict arteries or veins. Reactivity was not altered in arteries or veins from DOCA-salt mice. We next investigated the mechanism of increased venous reactivity to NE and PE by studying desensitization to maximum concentrations of NE and PE. Sham arteries desensitized to NE and PE more than DOCA-salt arteries, whereas DOCA-salt and sham veins maintained 80% of the initial NE and PE constriction. To determine whether the increased reactivity and resistance to desensitization in veins was due to a greater {alpha}-adrenoceptor reserve, vessels were incubated with the alkylating agent phenoxybenzamine (PBZ; 0.3, 3, 10, and 30 nM). The NE-elicited initial constriction was reduced by PBZ (3, 10, and 30 nM) in sham but only by PBZ (30 nM) in DOCA-salt veins. All doses of PBZ blocked NE responses in sham and DOCA-salt arteries. These data suggest that mesenteric veins express more {alpha}1-adrenoceptors than arteries, accounting for greater reactivity and resistance to desensitization compared with arteries.


Received June 25, 2003; accepted September 30, 2003.

Address correspondence to: Alex A. Pérez-Rivera, Michigan State University, Department of Pharmacology and Toxicology, B 440 Life Sciences, East Lansing, MI 48824. E-mail: perezriv{at}msu.edu




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Xu, G. D. Fink, and J. J. Galligan
Increased sympathetic venoconstriction and reactivity to norepinephrine in mesenteric veins in anesthetized DOCA-salt hypertensive rats
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H160 - H168.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.